SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 134 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $89,000 | -50.3% | 18,145 | -58.5% | 0.00% | -100.0% |
| Q2 2022 | $179,000 | -44.1% | 43,745 | -20.7% | 0.00% | 0.0% |
| Q1 2022 | $320,000 | -32.6% | 55,145 | -12.8% | 0.00% | -50.0% |
| Q4 2021 | $475,000 | -18.9% | 63,270 | -2.8% | 0.00% | -33.3% |
| Q3 2021 | $586,000 | +581.4% | 65,070 | +529.7% | 0.00% | +200.0% |
| Q4 2019 | $86,000 | -8.5% | 10,333 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $94,000 | -16.1% | 10,333 | -0.4% | 0.00% | 0.0% |
| Q2 2019 | $112,000 | +7.7% | 10,378 | -5.0% | 0.00% | 0.0% |
| Q1 2019 | $104,000 | -18.1% | 10,928 | -0.9% | 0.00% | 0.0% |
| Q4 2018 | $127,000 | -32.1% | 11,028 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $187,000 | +19.1% | 11,028 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $157,000 | -25.9% | 11,028 | -1.3% | 0.00% | 0.0% |
| Q1 2018 | $212,000 | +12.2% | 11,178 | -3.0% | 0.00% | 0.0% |
| Q4 2017 | $189,000 | +9.2% | 11,528 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $173,000 | +68.0% | 11,528 | -1.3% | 0.00% | +100.0% |
| Q2 2017 | $103,000 | +68.9% | 11,678 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $61,000 | +69.4% | 11,678 | -0.8% | 0.00% | 0.0% |
| Q4 2016 | $36,000 | -43.8% | 11,778 | -14.2% | 0.00% | 0.0% |
| Q3 2016 | $64,000 | -62.8% | 13,728 | -53.6% | 0.00% | -75.0% |
| Q2 2016 | $172,000 | +81.1% | 29,556 | +88.5% | 0.00% | +100.0% |
| Q1 2016 | $95,000 | -31.7% | 15,678 | +3.3% | 0.00% | -50.0% |
| Q4 2015 | $139,000 | +65.5% | 15,178 | +1.3% | 0.00% | +100.0% |
| Q3 2015 | $84,000 | -99.9% | 14,978 | -0.5% | 0.00% | -33.3% |
| Q2 2015 | $166,905,000 | +68303.7% | 15,050 | -3.2% | 0.00% | -40.0% |
| Q1 2015 | $244,000 | -99.9% | 15,550 | -6.0% | 0.01% | 0.0% |
| Q4 2014 | $251,726,000 | +45.4% | 16,550 | +3.1% | 0.01% | +25.0% |
| Q3 2014 | $173,099,000 | -27.1% | 16,050 | +3.2% | 0.00% | -20.0% |
| Q2 2014 | $237,449,000 | -9.1% | 15,550 | +7.6% | 0.01% | -16.7% |
| Q1 2014 | $261,256,000 | +30.2% | 14,450 | 0.0% | 0.01% | +20.0% |
| Q4 2013 | $200,711,000 | +32.4% | 14,450 | 0.0% | 0.01% | 0.0% |
| Q3 2013 | $151,581,000 | – | 14,450 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |